Inhibrx Biosciences director Jon Kayyem buys $500,000 in stock

Inhibrx Biosciences director Jon Kayyem recently acquired 5,000 shares of the company's common stock, purchasing them for $500,000 at a price of $100 per share on September 16, 2026. Despite the stock currently trading at $104.73, near Kayyem's purchase price, it has declined 6% over the past week. The Insider purchase comes as InvestingPro analysis indicates the stock is currently overvalued relative to its Fair Value, with a potential to provide valuable insights to investors seeking comprehensive valuation.

In recent news, Inhibrx Biosciences announced promising results from the Phase 2 portion of the HexAgon-HN trial, evaluating its drug INBRX-106 in combination with Keytruda for head and neck cancer, which showed a confirmed overall response rate of 48.3% and a median progression-free survival of 9.6 months, surpassing Keytruda alone.

Following these results, H.C. Wainwright reiterated its Buy rating for Inhibrx with a price target of $245.00, while Stifel maintained its Buy rating, setting a price target of $325.00.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.